Off-the-Shelf CAR-T cells take on tough blood cancers
NCT ID NCT06662227
First seen Jan 23, 2026 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along with short-term immunosuppression to prevent rejection. The main goals are to find a safe dose and check for any early signs that the treatment shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
universal CD19-targeted CAR-T cells (UWD-19) plus mycophenolate immunosuppression
What this could lead to
If successful, this could point toward a readily available 'off-the-shelf' cell therapy for hard-to-treat B-cell cancers, reducing the need for personalized manufacturing.
What could go wrong
This is a very early (Phase 1), small (30 people), suspended trial. CAR-T therapy carries risks of severe side effects like cytokine release syndrome and neurological problems. The universal approach may also be rejected by the immune system or lose effectiveness over time.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.